Although the US launch of Johnson & Johnson's CareAdvantage program seemed to get a greater share of the headlines during the global roll-out in spring 2017, the Europe-Middle East-Africa (EMEA) part of the initiative is quietly and efficiently penetrating both minds and markets in its target geography. (Also see "J&J Ups The Tempo In The March Toward Value-based Health Care" - In Vivo, 14 February, 2017.)
Hugo Breda, vice president of Johnson & Johnson's strategic capabilities for medical devices, EMEA, says that the Europe and beyond...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?